Navigation Links
Perrigo Company plc Reports Record Fourth Quarter And Fiscal Year Revenue, Adjusted Operating Income And Adjusted Margins. Conference call scheduled for 10 a.m. ET today.
Date:8/14/2014

/span>$

0.9 

 PERRIGO COMPANY PLCCONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY(in millions, except per share amounts)Common StockIssuedAccumulatedOtherComprehensiveIncome (Loss)RetainedEarningsTotalSharesAmountBalance at June 25, 2011

92.8$

467.7$

127.1$

934.3$

1,529.1Net income

401.6401.6Other comprehensive loss

(87.6)(87.6)Issuance of common stock under:Stock options

0.511.611.6Restricted stock plan

0.3Compensation for stock options

5.05.0Compensation for restricted stock

14.0

SOURCE Perrigo Company plc
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine technology :

1. Perrigo Company plc Reports Record Fourth Quarter And Fiscal Year Revenue, Adjusted Operating Income And Adjusted Margins
2. Perrigo Company plc Announces Quarterly Dividend
3. Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0%
4. Perrigo Company plc To Host Investor Day And To Present At The 32nd Annual J.P. Morgan Healthcare Conference
5. Updated Financial Standings, Company Announcements, and Customer-Centered Suggestions - Research Report on Perrigo, Thermo Fisher, DaVita, United Therapeutics, and Keryx Biopharmaceuticals
6. Perrigo Confirms Filing For Generic Version Of Acanya
7. Perrigo Shareholders Approve Proposals Related To Perrigos Proposed Acquisition Of Elan
8. Perrigo Company Announces Tender Offer and Consent Solicitation for its 2.950% Notes due 2023
9. Perrigo Initiates Nationwide Voluntary Product Recall Of Acetaminophen Infant Suspension Liquid, 160 mg/5 mL, Due To A Potential Defect With The Co-Packaged Oral Syringe
10. Perrigo Reports Record First Quarter Revenue, Adjusted Earnings And Margins
11. Perrigo Company To Release First Quarter Fiscal Year 2014 Results On October 31, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 22, 2014 Sanomedics International Holdings, Inc. (OTCQB: ... Global Research & Data Services, demand for thermometers is ... through 2018, as demand for more accurate digital thermometers ... the world,s largest market for thermometers, and one of ... Sanomedics International Holdings, Inc. Sanomedics International Holdings ...
(Date:10/22/2014)... NEW YORK , Oct. 22, 2014 ... and dermatology therapies. PV-10, its novel investigational drug for ... the potential for systemic side effects. Its oncology focus ... liver. Provectus has completed phase 2 trials of PV-10 ... as a topical treatment for atopic dermatitis and psoriasis. ...
(Date:10/22/2014)... LA JOLLA, Calif. , Oct. 22, ... RGLS ), a biopharmaceutical company leading ... targeting microRNAs, today announced that it has ... from an ongoing clinical study evaluating RG-101, ... for the treatment of hepatitis C virus ...
Breaking Medicine Technology:Sanomedics International Holdings Analyst Report: Taking Some Heat by BrokerBank Securities, Inc. 2Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8
... REO, a leading manufacturer of high volume ... to the newly created position of Vice President of ... aspects of the company,s optics fabrication, thin film coating ... served with Intel Corporation developing and implementing multiple technology ...
... 14 While Father,s Day gifts range from the touching ... is help and support during the difficult time of a cancer diagnosis. ... Often men have tremendous difficulties deciding ... Michael Diefenbach , Ph.D., associate professor of Urology at Mount Sinai School ...
Cached Medicine Technology:Mark Notarfrancesco Joins REO as VP Manufacturing Operations 2Prostate Cancer: The Father's Day Gift You Never Thought About 2
(Date:10/22/2014)... (PRWEB) October 22, 2014 On Saturday, October ... its fourth annual family health and fitness fair ¡Vive tu ... physical activity and good nutrition for better health and wellness ... which is free and open to the public, will be ... Brownsville, from 9:00 am to 1:00 pm. , “¡Vive ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 For Dr. Iris ... make money; it’s an extension of her life’s mission. Her ... venture as the owner of FirstLight HomeCare, make it clear ... important to me that my work makes a difference in ... an entrepreneurial spirit, so after much research, I felt ready ...
(Date:10/22/2014)... The Louis W. Sullivan Institute ... distribute health information technology innovation to transform quality ... development of six key guiding principles of patient-centered ... These are an expansion of the Institute of ... is respectful of and responsive to individual patient ...
(Date:10/22/2014)... Best Cheap Hosting USA is among ... site has recently announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) ... from around the world. , “iPower is one of ... is providing various kinds of useful products for new ... offering excellent customer service and a number of features ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Lintelus, Inc., ... Sr. Vice President of Sales, will be speaking on ... Meetings Technology Expo on October 28, at the Holiday ... hosting a booth as well as a Tech Demo ... Meeting can create a more engaging event experience. , ...
Breaking Medicine News(10 mins):Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2
... including Parkinson's, Alzheimer's, Diffuse Lewy body disease, and ... Most commonly they become symptomatic due to a ... case of Parkinson's it is dopamine. When the ... impaired, which occurs with oxidation, the eventual results ...
... to diagnose and many a times the diagnosis is ... emerging as a promising technique for early diagnosis of ... facilitating rapid amplification of small amounts of a genome ... Urology Congress in India. Presence of even one ...
... (PPA),is a common ingredient found in many non-prescription cough ... remedies increased the risk of stroke by 23 percent. ... says, "Case reports have linked exposure to PPA to ... ,A hemorrhagic stroke results when an artery wall ruptures ...
... of India has successfully undergone left knee joint replacement by ... "The operation, which started at around 10 a.m., was completed ... satisfaction," Dr. Ranawat said at a press briefing. ``He (Mr. ... now in the recovery room. He is not on any ...
... injectable contraceptive pill has been approved by the Food ... than 99 percent effective when women get the shot ... the pill., ,Lunelle is an alternative to another ... works Like many other birth control pills as it ...
... that more than two-thirds of births in Russia are marred ... clinic is suffering health problems. , ,The number of ... 30 percent last year, said Olga Frolova, head of the ... that the decline is due to the spread of heavy ...
Cached Medicine News:
Used for placement of choledochoscopes, cholangiography catheters and other instruments. Supplied sterile in peel-open packages. Intended for one-time use....
... for cholangiography and bile ... Dual lumen catheter design ... imaging and wire basket ... Supplied sterile in peel-open ...
... the MAMMOTOME® HH (Hand Held) ... procedure using ultrasound imaging for ... to locate breast abnormalities, you ... map the area you will ...
... Provides a more occlusive wrap than ... where wound transudate must be contained. Predictable ... be inert, nonantigenic, and nonpyrogenic. ,VICRYL (polyglactin ... synthetic absorbable copolymer of glycolide and lactide, ...
Medicine Products: